Yale Cancer Center ASCO Participation – 2018 Annual Meeting

Oral Abstract Sessions

Friday, June 1; 4:21 PM to 4:33 PM
Location: S404
State breast density inform mandate laws and utilization of adjunctive screening tests and cancer detection following screening mammography.
Cary Gross

Monday, June 4; 5:24 PM to 5:36 PM
Location: Arie Crown Theater
Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
Charles Fuchs

Tuesday, June 5; 8:24 AM to 8:36 AM
Location: S406
Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.
Brian Henick

Education Sessions

Friday, June 1; 4:30 PM to 4:50 PM
Location: S100a
Why Do We Care About Molecular Evolution in Breast Cancer?
Lajos Pusztai
**Poster Sessions**

**Saturday, June 2; 8:00 AM to 11:30 AM**
**Location:** Hall A

*Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.*

Xiaotong Li

**Saturday, June 2; 1:15 PM to 4:45 PM**
**Location:** Hall A

*Changes in access to care and financial hardship associated with Affordable Care Act (ACA) implementation for cancer survivors aged 19-64 years.*

Amy Davidoff

*Development of a dashboard for end-of-life care at an academic hospital.*

Kerin Adelson

*Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.*

Scott Huntington

*Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.*

Sarah Goldberg

*Breast Cancer Risk Perception and Adherence to U.S. Cancer Prevention Guidelines.*

Jillian Eckroate

**Sunday, June 3; 8:00 AM to 11:30 AM**
**Location:** Hall A

*Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).*

Stacey Stein

*Differential outcomes in patients with uncommon EGFR exon 19 mutations.*

Tyler Stewart

*Insurance disparity in cause-specific mortalities: A SEER study on early stage, non-elderly NSCLC cancer survivors.*

Changchuan Jiang

*NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.*

Michael Cecchini

*Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.*

Allison Campbell
Establishment of a medical student elective on the oncology consult service using the seven principles of teaching.

Hari Deshpande

Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.

Thuy Tran

Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

Roy S. Herbst

Patterns and determinants of pain and emotional distress in older adults with cancer: A population based study.

Amy Davidoff

A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.

Alessandro Santin

Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).

Ila Datar